ParkinsonCanadaV1, Main, Exploration, bibRecord, 000E81

5-Hydroxytryptamine 2A receptor antagonists as potential treatment for psychiatric disorders.

Identifieur interne : 000E81 ( Main/Exploration ); précédent : 000E80; suivant : 000E82

5-Hydroxytryptamine 2A receptor antagonists as potential treatment for psychiatric disorders.

Auteurs : Tiago A. Mestre [Canada] ; Mateusz Zurowski ; Susan H. Fox

Source :

Expert opinion on investigational drugs [ 1744-7658 ] ; 2013.

RBID : pubmed:23409724

English descriptors

KwdEn :
- Alzheimer Disease (drug therapy), Alzheimer Disease (metabolism), Humans, Mental Disorders (drug therapy), Mental Disorders (metabolism), Parkinson Disease (drug therapy), Parkinson Disease (metabolism), Receptor, Serotonin, 5-HT2A (metabolism), Serotonin Antagonists (therapeutic use).
MESH :
- chemical , metabolism : Receptor, Serotonin, 5-HT2A.
- drug therapy : Alzheimer Disease, Mental Disorders, Parkinson Disease.
- metabolism : Alzheimer Disease, Mental Disorders, Parkinson Disease.
- chemical , therapeutic use : Serotonin Antagonists.
- Humans.

Abstract

5-Hydroxytryptamine 2A receptors (5-HT2A-Rs) are widely expressed in the brain and have been implicated in mood and behavior. Based on the use of atypical antipsychotics in schizophrenia, antagonism of 5-HT2A-Rs initially emerged as a potential intervention capable of reducing the incidence of extrapyramidal symptoms, while exerting an effective antipsychotic action. More recently, highly selective 5-HT2A-R antagonists have been evaluated in the treatment of a wide range of other psychiatric disorders.

DOI: 10.1517/13543784.2013.769957
PubMed: 23409724

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">5-Hydroxytryptamine 2A receptor antagonists as potential treatment for psychiatric disorders.</title>
<author><name sortKey="Mestre, Tiago A" sort="Mestre, Tiago A" uniqKey="Mestre T" first="Tiago A" last="Mestre">Tiago A. Mestre</name>
<affiliation wicri:level="4"><nlm:affiliation>University of Toronto, Toronto Western Hospital and Division of Neurology, Movement Disorders Centre, Toronto, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>University of Toronto, Toronto Western Hospital and Division of Neurology, Movement Disorders Centre, Toronto, Ontario</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Zurowski, Mateusz" sort="Zurowski, Mateusz" uniqKey="Zurowski M" first="Mateusz" last="Zurowski">Mateusz Zurowski</name>
</author>
<author><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H" last="Fox">Susan H. Fox</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2013">2013</date>
<idno type="RBID">pubmed:23409724</idno>
<idno type="pmid">23409724</idno>
<idno type="doi">10.1517/13543784.2013.769957</idno>
<idno type="wicri:Area/PubMed/Corpus">000936</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000936</idno>
<idno type="wicri:Area/PubMed/Curation">000936</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000936</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000936</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000936</idno>
<idno type="wicri:Area/Ncbi/Merge">001386</idno>
<idno type="wicri:Area/Ncbi/Curation">001386</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001386</idno>
<idno type="wicri:Area/Main/Merge">000E93</idno>
<idno type="wicri:Area/Main/Curation">000E81</idno>
<idno type="wicri:Area/Main/Exploration">000E81</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">5-Hydroxytryptamine 2A receptor antagonists as potential treatment for psychiatric disorders.</title>
<author><name sortKey="Mestre, Tiago A" sort="Mestre, Tiago A" uniqKey="Mestre T" first="Tiago A" last="Mestre">Tiago A. Mestre</name>
<affiliation wicri:level="4"><nlm:affiliation>University of Toronto, Toronto Western Hospital and Division of Neurology, Movement Disorders Centre, Toronto, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>University of Toronto, Toronto Western Hospital and Division of Neurology, Movement Disorders Centre, Toronto, Ontario</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Zurowski, Mateusz" sort="Zurowski, Mateusz" uniqKey="Zurowski M" first="Mateusz" last="Zurowski">Mateusz Zurowski</name>
</author>
<author><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H" last="Fox">Susan H. Fox</name>
</author>
</analytic>
<series><title level="j">Expert opinion on investigational drugs</title>
<idno type="eISSN">1744-7658</idno>
<imprint><date when="2013" type="published">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Alzheimer Disease (drug therapy)</term>
<term>Alzheimer Disease (metabolism)</term>
<term>Humans</term>
<term>Mental Disorders (drug therapy)</term>
<term>Mental Disorders (metabolism)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (metabolism)</term>
<term>Receptor, Serotonin, 5-HT2A (metabolism)</term>
<term>Serotonin Antagonists (therapeutic use)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Receptor, Serotonin, 5-HT2A</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Alzheimer Disease</term>
<term>Mental Disorders</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Alzheimer Disease</term>
<term>Mental Disorders</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Serotonin Antagonists</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Humans</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">5-Hydroxytryptamine 2A receptors (5-HT2A-Rs) are widely expressed in the brain and have been implicated in mood and behavior. Based on the use of atypical antipsychotics in schizophrenia, antagonism of 5-HT2A-Rs initially emerged as a potential intervention capable of reducing the incidence of extrapyramidal symptoms, while exerting an effective antipsychotic action. More recently, highly selective 5-HT2A-R antagonists have been evaluated in the treatment of a wide range of other psychiatric disorders.</div>
</front>
</TEI>
<affiliations><list><country><li>Canada</li>
</country>
<region><li>Ontario</li>
</region>
<settlement><li>Toronto</li>
</settlement>
<orgName><li>Université de Toronto</li>
</orgName>
</list>
<tree><noCountry><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H" last="Fox">Susan H. Fox</name>
<name sortKey="Zurowski, Mateusz" sort="Zurowski, Mateusz" uniqKey="Zurowski M" first="Mateusz" last="Zurowski">Mateusz Zurowski</name>
</noCountry>
<country name="Canada"><region name="Ontario"><name sortKey="Mestre, Tiago A" sort="Mestre, Tiago A" uniqKey="Mestre T" first="Tiago A" last="Mestre">Tiago A. Mestre</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E81 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000E81 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:23409724
   |texte=   5-Hydroxytryptamine 2A receptor antagonists as potential treatment for psychiatric disorders.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:23409724" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a ParkinsonCanadaV1

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

La maladie de Parkinson au Canada (serveur d'exploration)

5-Hydroxytryptamine 2A receptor antagonists as potential treatment for psychiatric disorders.

5-Hydroxytryptamine 2A receptor antagonists as potential treatment for psychiatric disorders.

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.